文章核心观点 - 大型制药公司在靶向放射性药物这一新兴癌症治疗领域投入数十亿美元，RBC Capital Markets认为该领域有250亿美元的市场机会，各公司通过收购等方式布局，行业发展前景广阔 [1] 行业情况 - 靶向放射性药物疗法是将放射性粒子附着在靶向分子上，直接将辐射输送到肿瘤中，行业发展仍处于早期阶段，下一代技术有望推动该领域创造价值 [1] - 创新放射性药物去年获得5.18亿美元风险融资，较2017年的6300万美元增长722% [8] 公司动态 诺华（Novartis） - 已在市场上推出两款靶向放射疗法药物Pluvicto和Lutathera，Pluvicto 2023年销售额达9.8亿美元，接近畅销药地位，预计到2028年两款药物合计营收达50亿美元 [2] - 本月初以10亿美元收购临床前阶段公司Mariana Oncology，该公司专注开发治疗乳腺癌、前列腺癌和肺癌的放射性药物项目 [3] - 4月Lutathera获FDA批准用于儿科患者，上月表示将为Pluvicto提交扩大标签申请，用于前列腺癌的早期治疗 [9] 礼来（Eli Lilly） - 去年12月以14亿美元收购放射性药物公司Point Biopharma，收购前其靶向辐射药物PNT2002在转移性去势抵抗性前列腺癌的三期试验中达到主要终点 [4] - 本周宣布将向Aktis Oncology支付6000万美元，使用其新型迷你蛋白技术平台开发抗癌放射性药物 [5] 百时美施贵宝（Bristol - Myers Squibb） - 2月以41亿美元收购RayzeBio，获得其包括晚期靶向放射性药物疗法RYZ101在内的产品线，该疗法用于胃肠胰神经内分泌肿瘤，也在进行小细胞肺癌的一期试验 [6] 阿斯利康（AstraZeneca） - 3月宣布计划以24亿美元收购临床阶段生物制药公司Fusion Pharmaceuticals，该公司针对转移性去势抵抗性前列腺癌的潜在新疗法FPI - 2265正在进行二期临床试验 [7] 行业趋势与机会 - 诺华的成功引发竞争对手的“错失恐惧症”，大型制药公司纷纷积累该新疗法的能力 [4] - 上市公司和私营公司未来都可能成为收购目标，一些尚未开展放射性药物项目的大型制药公司可能对该领域感兴趣，已有项目的公司也会寻找更多靶点和管线项目来扩充产品组合 [8] - 部分公司开发针对相同靶点的疗法，如百时美的RayzeBio使用锕等α发射体替代Pluvicto和Lutathera使用的镥等β发射体，放射性药物还可与免疫疗法等其他治疗方法结合使用，未来有望用于治疗卵巢癌、乳腺癌或脑癌等 [10] - 公司可利用过去30到40年癌症研究成果，识别癌细胞上的靶点，为靶向放射疗法创造机会 [11]

This top pharma stock has fallen too far.Dividend stocks are an important anchor for well-balanced portfolios. Regular cash distributions can buffer a portfolio against market volatility and provide a steady income across business cycles.Still, picking dividend stocks is no easy task. Companies operating in high-tech areas like healthcare often face unique competitive pressures that can diminish free cash flows, lowering their ability to reward shareholders via ever-larger dividend checks. Bristol Myers Squ ...

Bristol Myers Squibb (BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.The subcutaneous formulation of Opdivo is co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20). The BLA seeks approval of the same across all previously approved adult, solid tumor indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or i ...

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selectionLONDON, May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair ('MMR' ...

Key PointsPerspective Therapeutics' major shareholder doubled down on the position, validating the business and pipeline. Liberty Live Group's SiriusXM stock is bought by Warren Buffett and Berkshire Hathaway. NB Bancorp is an aged institution that recently IPOd with great success; it is still undervalued. The threat of fines and imprisonment, up to twenty years for the worst offenders, makes insider trading a different game than what it was. Today, insiders must reveal their trading within days of executio ...

Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to the label expansion of chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The regulatory body approved Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approv ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

新产品和新技术研发 - 公司引入新产品如KarXT、Opdualag、Camzyos和Reblozyl[4] - Opdivo的皮下制剂PDUFA日期定于2025年2月，将为公司增长提供补充[15] - 公司对Breyanzi的长期潜力感到兴奋，认为产品在高需求病人群体中将获得优先考虑[36] - 公司对细胞疗法作为未来增长平台持乐观态度，认为市场准入和定价补偿将继续改善[38] - 公司目前主要关注Opdualag和将其应用于其他肿瘤类型，预计在该领域持续增长[40] - 公司看好RayzeBio和Ray Ligand的潜力，认为市场巨大，产品获批后将在多个IND引擎和多种肿瘤类型中发挥作用[42] - Camzyos的安全性和疗效表现强劲，患者使用后持续疗程延长，公司将继续积累真实世界数据以加强产品安全性[44] - Camzyos产品推出几年后，公司计划继续扩大市场覆盖范围，力争使其成为该重要市场的首选产品[45] - KarXT的PDUFA日期较晚，公司将其视为2025年的产品推出，预计在未来几年内逐步获得各州的表格批准[54] - KarXT在阿尔茨海默病领域有巨大机会，公司计划在未来几年内公布相关Phase 3研究数据[56] - CD19 NEX-T的构造与Breyanzi相似，公司认为其有望重置患者免疫系统，对自身免疫疾病和多发性硬化等疾病患者有重要意义[69] 业绩总结 - Opdivo业务预计在未来继续增长，尤其在早期治疗领域[13] - Reblozyl在早期贫血治疗领域表现出色，市场渗透率仅为25%[18] - Breyanzi被视为公司的重要增长驱动力，具有高安全性和供应无限制[28] 市场扩张和并购 - 公司在扩大Breyanzi供应方面取得进展，包括建设新的制造设施和自动化制造流程[29][30] - 公司认为竞争对手产品的推出有助于提高患者意识，长期来看对患者将是有益的[46] - Camzyos新患者启动速度逐渐增加，公司通过直接到消费者的投资提高了疾病和产品的认知度[48]

Give someone a dividend and you pay them that day but teach them to capture the dividend and you provide investment income for life!Executing a capture-the-dividend trade entails buying the stock before the ex-date so you are the shareholder of record. You then sell it to book the dividend income, making little if any capital gains (that would be nice but it is not the objective). There are many factors to consider in buying dividend stocks for tactical traders.  The bigger the dividend the bigger the profi ...

业务发展 - RayzeBio是Bristol-Myers Squibb公司的独立子公司，致力于放射治疗领域，Bristol希望通过收购RayzeBio来拓展放射治疗领域的机会[5] - RayzeBio的技术基于actinium-225，相比于lutetium-177具有更高的能量释放，能够创造更持久的治疗效果，同时具有更长的半衰期，有利于全球市场供应[11] - RayzeBio在放射治疗领域有领先地位，计划快速扩展研发管线，探索更多潜在靶点，并加速研究团队的扩张[33] 产品研发 - RZY101在GEP-NETs的Phase 3研究中是以PFS为终点，目前正在全球范围内进行招募，预计2026年公布数据，可能会有中期分析[14] - RayzeBio的另一项目RYZ801针对肝细胞癌，采用GPC3治疗方案，预计将在今年下半年提交IND，有望填补肝癌领域的治疗需求[27] 生产与供应链 - RayzeBio在印第安纳州拥有一座全新的制造工厂，用于生产actinium-225，以确保临床和商业需求，同时与多家供应商签订协议，确保供应链的稳定性[35] - RayzeBio计划建立全球物流体系，确保患者能够及时获得治疗，同时在制造和供应链方面借鉴CAR T细胞治疗的经验[37] 成本与盈利模式 - RZY101的成本预计与Lutathera相当，但由于使用更少的actinium，未来将实现更可持续和盈利的业务模式[40] 合作与发展 - RayzeBio非常专注于内部执行，确保长期锕供应，加速101研究的临床试验招募[42] - RayzeBio在放射治疗领域有专门团队，正在考虑许可和合作选择[42]